On this episode of Stock Movers:
- Kering agreed to sell its beauty division to L’Oreal SA as part of a long-term strategic alliance, its stock having risen about 36% since the start of the year. 
_ Holcim is set to acquire Xella, a European walling systems company, in a €1.85 billion ($2.2 billion) deal expanding its building solutions business following the spin off of its North American unit.
- TKMS, Germany's largest warship-maker and the spin-off of defence group Thyssenkrupp, rose as high as €75 a share up from €60 in the first minutes of its trading debut.

On this episode of Stock Movers: - Kering agreed to sell its beauty division to L&rsquo;Oreal SA as part of a long-term strategic alliance, its stock having risen about 36% since the start of the year. _ Holcim is set to acquire Xella, a European walling systems company, in a &euro;1.85 billion ($2.2 billion) deal expanding its building solutions business following the spin off of its North American unit. - TKMS, Germany's largest warship-maker and the spin-off of defence group Thyssenkrupp, rose as high as &euro;75 a share up from &euro;60 in the first minutes of its trading debut.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Kering Up, Holcim Gains, TKMS Rises

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/905410cc-9e57-4a00-8ea8-b37c00956eb5/transcript

On this episode of Stock Movers:
- Shares of Nvidia (NVDA) edge higher in the premarket session as the company agreed to a licensing deal with artificial intelligence startup Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products.
- Shares of Indian technology services provider Coforge Ltd. (COFORGE IN) declined ahead of the US market open after the company agreed to buy Encora at an enterprise value of $2.35 billion in an all-stock deal, adding artificial intelligence, data and product engineering expertise. Encora’s shareholders, including Advent International and Warburg Pincus, will get about 20% stake in Coforge through a share swap. Coforge will issue 93.8 million shares at 1,815.91 rupees each to shareholders of Encora at equity value of $1.89 billion. The deal is expected to close in six months.
- Shares of Biohaven (BHVN) fell as much 14 percent in US premarket trading after a mid-stage study of the company’s experimental drug BHV-7000 for the treatment of major depressive disorder missed the primary endpoint. Trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline, on primary and secondary outcome measures.

On this episode of Stock Movers: - Shares of Nvidia (NVDA) edge higher in the premarket session as the company agreed to a licensing deal with artificial intelligence startup Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products. - Shares of Indian technology services provider Coforge Ltd. (COFORGE IN) declined ahead of the US market open after the company agreed to buy Encora at an enterprise value of $2.35 billion in an all-stock deal, adding artificial intelligence, data and product engineering expertise. Encora&rsquo;s shareholders, including Advent International and Warburg Pincus, will get about 20% stake in Coforge through a share swap. Coforge will issue 93.8 million shares at 1,815.91 rupees each to shareholders of Encora at equity value of $1.89 billion. The deal is expected to close in six months. - Shares of Biohaven (BHVN) fell as much 14 percent in US premarket trading after a mid-stage study of the company&rsquo;s experimental drug BHV-7000 for the treatment of major depressive disorder missed the primary endpoint. Trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline, on primary and secondary outcome measures.

Nvidia Agrees to Groq Licensing Deal; India's Coforge Buys Encora; Biohaven Tumbles

On this episode of Stock Movers:
- Shares of Nvidia (NVDA) edge higher in the premarket session as the company takes agreed to a licensing deal with artificial intelligence startup Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products. 
- Shares of Sidus Space (SIDU) rallied as much as 30 percent ahead of the US market open after the Cape Canaveral, Florida-based space and defense tech company announced plans to raise capital through a public offering of its Class A common stock and or pre-funded warrants.
- Shares of Biohaven (BHVN) fell as much 14 percent in US premarket trading after a mid-stage study of the company’s experimental drug BHV-7000 for the treatment of major depressive disorder missed the primary endpoint. Trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline, on primary and secondary outcome measures.

On this episode of Stock Movers: - Shares of Nvidia (NVDA) edge higher in the premarket session as the company takes agreed to a licensing deal with artificial intelligence startup Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products. - Shares of Sidus Space (SIDU) rallied as much as 30 percent ahead of the US market open after the Cape Canaveral, Florida-based space and defense tech company announced plans to raise capital through a public offering of its Class A common stock and or pre-funded warrants. - Shares of Biohaven (BHVN) fell as much 14 percent in US premarket trading after a mid-stage study of the company&rsquo;s experimental drug BHV-7000 for the treatment of major depressive disorder missed the primary endpoint. Trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline, on primary and secondary outcome measures.

Nvidia Edges Higher; Sidus Space Rallies; Biohaven Slips on Study

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/022de151-e912-4b2c-9c2c-b3bf00c914c4/transcript

- Nike (NKE) shares got a boost on Wednesday after a filing showed that Apple CEO Tim Cook purchased $2.95 million worth of shares on Dec. 22. Cook is Nike’s lead independent director and served as a director since 2005, according to the company’s website. The filing shows Cook purchased 50,000 Class B common stock at a weighted average price of $58.97.
- Costco (COST) rose after receiving an upgrade for Christmas, as Northcoast Research analyst Charles Cerankosky raised the recommendation on wholesale giant to buy from neutral. His new price target of $1,100 implies a 29% increase from Tuesday's closing price. Investors who followed Cerankosky's recommendation received a 0% return in the past year, compared with a negative 9.5% return on the shares.
- Dynavax (DVAX) popped after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm’s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.

- Nike (NKE) shares got a boost on Wednesday after a filing showed that Apple CEO Tim Cook purchased $2.95 million worth of shares on Dec. 22. Cook is Nike&rsquo;s lead independent director and served as a director since 2005, according to the company&rsquo;s website. The filing shows Cook purchased 50,000 Class B common stock at a weighted average price of $58.97. - Costco (COST) rose after receiving an upgrade for Christmas, as Northcoast Research analyst Charles Cerankosky raised the recommendation on wholesale giant to buy from neutral. His new price target of $1,100 implies a 29% increase from Tuesday's closing price. Investors who followed Cerankosky's recommendation received a 0% return in the past year, compared with a negative 9.5% return on the shares. - Dynavax (DVAX) popped after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm&rsquo;s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.

Nike Jumps, Costco Upgraded, Dynavax Soars

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/75459fc1-6a79-4d0a-a10a-b3bd01160eed/transcript

Kering Up, Holcim Gains, TKMS Rises

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips